Literature DB >> 29502072

Electroacupuncture mitigates endothelial dysfunction via effects on the PI3K/Akt signalling pathway in high fat diet-induced insulin-resistant rats.

Danchun Lan1, Wei Yi2, Nenggui Xu2, Jian Sun3, Zhixing Li4, Rongzhen Liao5, Hongtao Zhang2, Xiaoli Liang2.   

Abstract

OBJECTIVE: To investigate the effect of electroacupuncture (EA) on endothelial dysfunction related to high fat diet (HFD)-induced insulin resistance through the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signalling pathway.
METHODS: Twenty-four male Sprague-Dawley rats were fed a regular diet (Control group, n=8) or a HFD (n=16) for 12 weeks to induce an insulin resistance model. HFD-fed rats were divided into two groups that remained untreated (HFD group, n=8) or received electroacupuncture (HFD+EA group, n=8). EA was applied at PC6, ST36, SP6 and BL23. At the end of the experiment, fasting blood glucose (FBG), serum insulin (FINS), serum C-peptide (C-P) and homeostatic model assessment of insulin resistance (HOMA-IR) indices were determined. Pancreatic islet samples were subjected to histopathological examination. The thoracic aorta was immunostained with anti-rat insulin receptor substrate (IRS)-1, Akt and endothelial nitric oxide synthase (eNOS) antibodies. mRNA and protein expression of IRS-1, PI3K, Akt2 and eNOS in the vascular endothelium were determined by real-time PCR and Western blot analysis, respectively.
RESULTS: The bodyweight increase of the HFD+EA group was smaller than that of the untreated HFD group. Compared with the HFD group, the levels of FBG, FINS, C-P and HOMA-IR in the HFD+EA group decreased significantly (P<0.01). Histopathological evaluation indicated that EA improved pancreatic islet inflammation. The expression of endothelial markers, such as IRS-1, PI3K, Akt2 and eNOS, decreased in the HFD group, while EA treatment appeared to ameliorate the negative impact of diet.
CONCLUSION: EA may improve insulin resistance and attenuate endothelial dysfunction, and therefore could play a potential role in the prevention or treatment of diabetic complications and cardiovascular disease through the PI3K/Akt signalling pathway. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  diabetes; electroacupuncture

Mesh:

Substances:

Year:  2018        PMID: 29502072     DOI: 10.1136/acupmed-2016-011253

Source DB:  PubMed          Journal:  Acupunct Med        ISSN: 0964-5284            Impact factor:   2.267


  5 in total

1.  Clinical efficacy and safety of electro-acupuncture combined with beraprost sodium and α-lipoic acid for diabetic peripheral neuropathy.

Authors:  Zhenzhai Wang; Yixiang Hou; Yalian Huang; Feng Ju; Zunxiao Liang; Songting Li
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 2.  Acupoint Therapy on Diabetes Mellitus and Its Common Chronic Complications: A Review of Its Mechanisms.

Authors:  Yiyi Feng; Yuchen Fang; Yiqin Wang; Yiming Hao
Journal:  Biomed Res Int       Date:  2018-10-22       Impact factor: 3.411

Review 3.  The Anti-Inflammatory Actions and Mechanisms of Acupuncture from Acupoint to Target Organs via Neuro-Immune Regulation.

Authors:  Ningcen Li; Yi Guo; Yinan Gong; Yue Zhang; Wen Fan; Kaifang Yao; Zhihan Chen; Baomin Dou; Xiaowei Lin; Bo Chen; Zelin Chen; Zhifang Xu; Zhongxi Lyu
Journal:  J Inflamm Res       Date:  2021-12-21

4.  Determination of Electroacupuncture Effects on circRNAs in Plasma Exosomes in Diabetic Mice: An RNA-Sequencing Approach.

Authors:  Yin Shou; Li Hu; Weibo Zhang; Yuan Gao; Ping Xu; Bimeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-24       Impact factor: 2.629

5.  Electroacupuncture Alleviates Diabetic Peripheral Neuropathy by Regulating Glycolipid-Related GLO/AGEs/RAGE Axis.

Authors:  Xuan Wang; Qian Li; Xu Han; Meirong Gong; Zhi Yu; Bin Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-06       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.